Erdheim-Chester Disease Involving Lymph Nodes and Liver Clinically Mimicking Lymphoma: A Case Report
0
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Erdheim-Chester disease (ECD) is a rare non-Langerhans cell histiocytosis and multisystem disease. First described in 1930, there are no more than 750 cases reported. The etiology remains unknown, but a majority of cases of ECD and Langerhans cell histiocytosis were found to have clonal mutations involving genes of the mitogen-activated protein kinase pathway. We recently encountered a 53-year-old male patient with extensive ECD involving the systemic lymph nodes, pleura, liver, and long bones clinically mimicking malignant lymphoma. Biopsies were performed at multiple sites, including a pleural mass, an external iliac lymph node, bone marrow, and the liver. Based on histopathological and immunohistochemical findings of positivity for CD68 and negativity for CD1a and S-100, the patient was diagnosed with ECD. Interferon-α was administered as the first-line treatment, but the patient rapidly progressed to hepatic failure after 2 months of treatment. We report this rare case of ECD clinically mimicking malignant lymphoma and diagnosed by careful pathological review.
Abstract
Erdheim-Chester disease (ECD) is a rare non-Langerhans cell histiocytosis and multisystem disease. First described in 1930, there are no more than 750 cases reported. The etiology remains unknown, but a majority of cases of ECD and Langerhans cell histiocytosis were found to have clonal mutations involving genes of the mitogen-activated protein kinase pathway. We recently encountered a 53-year-old male patient with extensive ECD involving the systemic lymph nodes, pleura, liver, and long bones clinically mimicking malignant lymphoma. Biopsies were performed at multiple sites, including a pleural mass, an external iliac lymph node, bone marrow, and the liver. Based on histopathological and immunohistochemical findings of positivity for CD68 and negativity for CD1a and S-100, the patient was diagnosed with ECD. Interferon-α was administered as the first-line treatment, but the patient rapidly progressed to hepatic failure after 2 months of treatment. We report this rare case of ECD clinically mimicking malignant lymphoma and diagnosed by careful pathological review.
참고문헌 (20)
- Campochiaro C, "Erdheim-Chester disease", Eur J Intern Med, 26, pp.223~229 (2015)[DOI]
- 임진, "A Unique Case of Erdheim-Chester Disease with Axial Skeleton, Lymph Node, and Bone Marrow Involvement", Cancer Research and Treatment, 48(1), pp.415~421 (2016), 대한암학회[DOI]
- Bindra J, "Erdheim-Chester disease: an unusual presentation of an uncommon disease", Skeletal Radiol, 43, pp.835~840 (2014)[DOI]
- Pavlidakey PG, "Erdheim-chester disease associated with marginal zone lymphoma and monoclonal proteinemia", Case Rep Hematol, 2011 (2011)
- Haroche J, "Erdheim-Chester disease", Presse Med, 36, pp.1663~1668 (2007)[DOI]
- Sheu SY, "Erdheim-Chester disease: case report with multisystemic manifestations including testes, thyroid, and lymph nodes, and a review of literature", J Clin Pathol, 57, pp.1225~1228 (2004)[DOI]
- Ivan D, "Erdheim-Chester disease: a unique presentation with liver involvement and vertebral osteolytic lesions", Arch Pathol Lab Med, 127, pp.e337~e339 (2003)
- Diamond EL, "Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease", Blood, 124, pp.483~492 (2014)[DOI]
- 차윤진, "Rosai-Dorfman Disease in the Breast with Increased IgG4 Expressing Plasma Cells: A Case Report", Journal of Pathology and Translational Medicine, 46(5), pp.489~493 (2012), 대한병리학회[DOI]
- Haroche J, "Imatinib mesylate for platelet-derived growth factor receptor-beta-positive Erdheim-Chester histiocytosis", Blood, 111, pp.5413~5415 (2008)
- Arnaud L, "CNS involvement and treatment with interferon-alpha are independent prognostic factors in Erdheim-Chester disease: a multicenter survival analysis of 53 patients", Blood, 117, pp.2778~2782 (2011)[DOI]
- Emile JF, "Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages", Blood, 127, pp.2672~2681 (2016)[DOI]
- Hervier B, "Association of both Langerhans cell histiocytosis and Erdheim-Chester disease linked to the BRAFV600E mutation", Blood, 124, pp.1119~1126 (2014)[DOI]
- Emile JF, "Recurrent RAS and PIK3CA mutations in Erdheim-Chester disease", Blood, 124, pp.3016~3019 (2014)[DOI]
- Munoz J, "Erdheim-Chester disease: characteristics and management", Mayo Clin Proc, 89, pp.985~996 (2014)[DOI]
- Tzoulis C, "Excellent response of intramedullary Erdheim-Chester disease to vemurafenib: a case report", BMC Res Notes, 8, pp.171~ (2015)[DOI]
- Nordmann TM, "Trametinib after disease reactivation under dabrafenib in Erdheim-Chester disease with both BRAF and KRAS mutations", Blood, 129, pp.879~882 (2017)[DOI]
- Cohen-Aubart F, "Variability in the efficacy of the IL1 receptor antagonist anakinra for treating Erdheim-Chester disease", Blood, 127, pp.1509~1512 (2016)[DOI]
- Janku F, "Response of histiocytoses to imatinib mesylate: fire to ashes", J Clin Oncol, 28, pp.e633~e636 (2010)[DOI]
- Haroche J, "Histiocytoses: emerging neoplasia behind inflammation", Lancet Oncol, 18, pp.e113~e125 (2017)[DOI]